Red Hill Biopharma Acquires Mesupron Pancreatic Cancer Treatment From Wilex AG

July 1, 2014 | Israeli bio-pharmaceutical company Red Hill Biopharma acquired Phase II oncology drug, Mesupron from Wilex AG. Mesupron has already completed a number of Phase I and Phase II clinical trials for the treatment of non-metastatic pancreatic cancer. Red Hill has acquired the exclusive development and commercialization rights for Mesupron, except in China, Hong Kong, Taiwan and Macao, for nearly $1 million from Wilex AG. The Israeli company, founded in 2009, will be responsible for the development, regulation and commercialization of Mesupron.